|
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus |
Patel DA, Shorr AF, Chastre J, Niederman M, Simor A, Stephens JM, Charbonneau C, Gao X, Nathwani D |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Patel DA, Shorr AF, Chastre J, Niederman M, Simor A, Stephens JM, Charbonneau C, Gao X, Nathwani D. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Critical Care 2014; 18(4): R157 Indexing Status Subject indexing assigned by NLM MeSH Acetamides /administration & Anti-Bacterial Agents /administration & Cost-Benefit Analysis /methods; Cross Infection /drug therapy /economics; Double-Blind Method; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus /drug effects; Models, Economic; Oxazolidinones /administration & Pneumonia, Staphylococcal /drug therapy /economics; Prospective Studies; Vancomycin /administration & dosage /economics; dosage /economics; dosage /economics; dosage /economics AccessionNumber 22014035977 Date bibliographic record published 21/11/2014 |
|
|
|